Table 1

Development of biologics active against Th17 pathway targets

Biologic agent	Developer	Psoriasis	PsA	AS	RA	IBD	Other indications
Anti-IL-17A mAb
Secukinumab [AIN457, KB03303A] (Consentyx)	Novartis	Marketed	Marketed	Marketed	P-III	Discontinued (CD)	Alopecia areata (P-II) Atopic dermatitis (P-II)
Ixekizumab [LY2439821] (Taltz)	Eli Lily	Marketed	P-III (submitted)	P-III	P-II
CNTO 6785	Janssen, MorphoSys				P-II		COPD (P-II)
CJM112	Novartis	P-I/II					Acne (P-II) Hydradenitis suppurativa (P-II)
BCD 085	Biocad	P-II		P-II
SCH-900117	Merck & Co				P-I
Perakizumab [RG 4934, RO 5310074]	Roche		Discontinued
Dual anti-IL-17A and anti-IL-17F mAb
Bimekizumab [CDP-4940, UCB-4940]	UCB	P-II	P-II	P-II	P-II	P-II (UC)
ALX-0761 [MSB-0010841, M-1095]	Merck Serono, Ablynx	P-I
RG 7624 [NI-1401, MCAF-5352A]	Genentech, NovImmune SA	Preclinical
Dual IL-17A and TNF-α mAb
ABT-122	AbbVie		P-II		P-II
COVA322	Janssen	P-I/II
ABBV-257	AbbVie				P-I
LY 3114062*	Eli Lilly						‘Inflammatory arthritis’ (P-I)
Anti-IL-17RA mAb
Brodalumab [AMG 827, KHK4827] (Lumicef, Siliq, Kyntheum)	AstraZeneca, Kyowa Hakko Kirin, Valeant Pharmaceuticals, LEO Pharma	Marketed	Marketed†	P-III	Discontinued	Discontinued (CD)
Anti-IL-12/23p40 mAb
Ustekinumab [CNTO-1275] (Stelara)	Janssen	Marketed	Marketed	P-III	Discontinued	Marketed (CD) P-III (UC)	SLE (P-II) Atopic dermatitis (P-II)
Briakinumab [ABT-874, A-796874.0, BSF415977, J695, LU415977, WAY-165772] (Ozespa)	Abbott	P-III (submission withdrawn)			Discontinued	Discontinued (CD)
Anti-IL-23 mAb
Guselkumab [CNTO-1959]	Janssen, MorphoSys	P-III (submitted)	P-II		P-II
Tildrakizumab [SCH-900222, MK-3222]	Merck, Sun Pharmaceutical Industries	P-III (submitted)	P-II	P-II
Brazikumab [AMG 139, MEDI2070]	Allergan, AstraZeneca, Amgen					P-II (CD)
Risankizumab [ABBV 066, BI 655066]	Boehringer Ingelheim, AbbVie	P-III	P-II	P-II		P-II (CD)	Asthma (P-II)
Mirikizumab [LY 3074828]	Eli Lilly	P-II				P-II (CD and UC)

Adapted from Refs 4 6 122 123. Development status based on http://adisinsight.springer.com, accessed 30 May 2017.
*LY3114062 mechanism of action is not yet disclosed, but believed to be a dual IL-17/TNF-α inhibitor.
†Brodalumab approved for treatment of psoriatic arthritis in Japan, although currently not approved for this indication in USA or Europe.
AS, ankylosing spondylitis; CD, Crohn’s disease; COPD, chronic obstructive pulmonary disease; IBD. inflammatory bowel disease; IL, interleukin; P-I, phase I clinical trial; P-II, phase II clinical trial; P-III, phase III clinical trial; PsA, psoriatic arthritis; mAb, monoclonal antibody; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; Th, T-helper; TNF, tumour necrosis factor; UC, ulcerative colitis.